Flagship Pioneering

Flagship announces Ponsi Trivisvavet, President & CEO of #FlagshipFounded Inari, as 2024 Pioneering Leader of the Year. Ponsi is recognized for her visionary leadership and transformative work as Inari revolutionizes agriculture through sustainable innovations in seed design. Under Ponsi’s guidance since 2018, the team at Inari has developed cutting-edge solutions to enhance plant breeding, emphasizing food system sustainability. For more: https://bit.ly/3CBnM1b Hear from Ponsi and other leaders of Flagship-founded agriculture companies in a short film on Flagship’s vision for a sustainable future in agriculture and the people and technologies that are making that vision a reality today: https://bit.ly/3XLSoEc

We’re pleased to share that Flagship Pioneering has named our CEO Ponsi Trivisvavet their 2024 Pioneering Leader of the Year! Congratulations to Ponsi on this much-deserved honor – your visionary leadership and dedication to a sustainable future for agriculture inspires us all. Learn more: https://lnkd.in/dpwJjSUJ

Join us in welcoming Angela Hwang as Chief Executive Officer of Metaphore. Angela comes to Metaphore after being Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer and a member of Pfizer’s Executive Leadership Team. Her decades of experience in developing new medicines and delivering them to patients with unmet need will be invaluable as we advance our MIMIC™ platform to pioneer novel therapeutics for maximum patient impact.    Learn more about Angela and her plans for #FlagshipFounded Metaphore: https://lnkd.in/eywhZFs5

Congratulations to the team at #FlagshipFounded Quotient Therapeutics on being named as Biotech Startup of the Year by BioTech Breakthrough Awards.

Exciting news from Montai! Today we announced a new research collaboration with Pfizer and Flagship Pioneering. This effort will leverage our AI-driven platform to discover untapped diverse chemistry that could become breakthrough small molecule solutions for lung cancer. Read the full announcement here: https://lnkd.in/eFxYDFGv #FlagshipFounded

Today, we announced a new collaboration under the Flagship Pioneering-Pfizer partnership to leverage our AND™ Platform to identify programmable biologics for the treatment of obesity. Our AND-Body™ Therapeutics are designed to target disease sites precisely, to drive better activity without affecting healthy tissues or cells. This collaboration is just one of many potential applications of our platform in obesity and beyond. Read more about our first partnership and learn how we’re unlocking novel approaches to targets in disease areas of significant unmet need: https://bit.ly/3YWeGni #Biotech #Innovation #DrugDevelopment #FlagshipFounded

Flagship announces Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies, effective January 1, 2025. Read the full announcement: https://bit.ly/4fA0szH

#FlagshipFounded Ampersand Biomedicines and Montai Therapeutics have entered into two new agreements under Flagship’s strategic partnership with Pfizer.    Ampersand’s AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets, and Montai’s CONECTA™ AI platform will be used to identify small molecules directed to a potential non-small cell lung cancer-related target. For more on both agreements: https://bit.ly/4fyuMKR

Meet some of the Flagship Fellows who joined us last summer for a hands-on experience working with our venture creation teams to apply their scientific imagination to pioneering new solutions for human health and sustainability. From mammalian embryology to immunology to electrical engineering, the Flagship Fellowship brings together individuals from a diversity of backgrounds and areas of study to work together to take scientific leaps. Applications to our 2025 Flagship Fellowship are open. Learn more, including about the application process and upcoming info sessions: bit.ly/FSPFellowship #FlagshipFellowship

Hear from Qasim Rizvi, CEO of #FlagshipFounded KSQ Therapeutics, Inc., on how the company’s CRISPRomics® platform seeks to identify gene targets for drug development and the role of tumor infiltrating lymphocytes (TILs) in the solid tumor space in this BiotechTV episode with Brad Loncar.     Hear more from Qasim on KSQ's approach to drug development, how eTIL® is transforming the treatment of solid tumors, and an experience that shaped him as a leader: https://lnkd.in/eMhVw7wd